Neuvasq Presents Data Showcasing Promising Novel Multispecific Gpr124-Targeting Antibodies for Blood Retina Barrier Restoration at ARVO 2026

Neuvasq Presents Data Showcasing Promising Novel Multispecific Gpr124-Targeting Antibodies for Blood Retina Barrier Restoration at ARVO 2026

Gosselies, Belgium, May 05, 2026 (GLOBE NEWSWIRE) -- Gpr124 represents a promising novel target for improving the integrity and function of the blood-retina barrier (BRB) with the...

Neuvasq Highlights Data for Targeting Antibodies for Blood Retina Barrier Restoration at ARVO

Key Takeaways Neuvasq presented new preclinical data at ARVO showing that targeting the Wnt co-receptors Gpr124 and Lrp6 may help repair and maintain the blood-retina barrier in retinal vascular diseases such as DME and wet AMD The company’s lead bispecific antibody candidate, NVQ401, demonstrated potent Wnt pathway activation and reversed vascular leakage  NVQ501 combined β-catenin activation with anti-VEGF activity, delivering enhanced effic…